Business
Telo Genomics Reports Substantial Progress Toward Clinical Launch of TeloView-SMM
Toronto, Ontario--(Newsfile Corp. - August 29, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: T...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Reports Substantial Progress Toward Clinical Launch of TeloView-SMMToronto, Ontario--(Newsfile Corp. - August 29, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo\") is pleased to provide an update on the planned launch of the TeloView®SMM (Smoldering Multiple Myeloma) assay in the fourth quarter of this year. The test will be introduced to clinicians as a Research Use Only (RUO) tool via Telo's new physician experience program. The program, designated as SMART (Smoldering Multiple myeloma Assessment of Risk for Transformation), is intended for oncology/hematology physicians and their staff in the U.S. to gain experience ordering and utilizing the TeloView SMM assay.Telo's CEO Kris Weinberg said, \"The planned 2023 launch of SMART along with recent presentations of data at ASCO and EHA are important steps in building Telo's commercial presence in the U.S. Working with a select group of physicians and facilities, the SMART program will gather information and feedback that are critical to the successful launch of TeloView-SMM.\"About TeloView-SMMTeloView-SMM has the potential to be an important tool for physicians managing the care of patients diagnosed with Smoldering Multiple Myeloma. The proprietary assay (and associated platform technology) quantifies individual patients' risk of transformation/progression by measuring the 3D structure and spatial organization of telomeres. This molecular signature identifies high-risk SMM patients who are likely to benefit from earlier treatment intervention. The larger subset of low-risk patients may not require immediate treatment and can be regularly monitored using the TeloView-SMM assay along with standard phenotypic measures. Over 200,000 patients in the United States are currently living with smoldering Multiple Myeloma. The TeloView-SMM assay has a potential total addressable market of over 500,000 tests per year.About Telo GenomicsTelo Genomics is a clinical-stage high complexity laboratory pioneering the most comprehensive telomere platform in the industry. The company has developed powerful predictive and prognostic assay tools in oncology and neurological disease. These applications are facilitated on a liquid biopsy platform that performs quantitative analysis of 3D telomeres with molecular biology and artificial intelligence t...